AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2020
Mar 10, 2020
30751_dirs_2020-03-10_1a157afb-eae7-4515-bd89-99711658be3d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2020-03-06
Reporting Person: Carr Patricia (VP, Finance & PAO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-06 | Ordinary Shares | S | 232 | $119.1732 | Disposed | 7668 | Direct |
| 2020-03-09 | Ordinary Shares | S | 568 | $111.4481 | Disposed | 7100 | Direct |
Footnotes
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $111.4401 to $111.4550. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.